MedTrace Logo

Fish Oil for the Treatment of Depression in Patients With Multiple Sclerosis

NCT00122954 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 39

Last updated 2017-06-08

Study results available
· View outcomes & findings →

Summary

This study will determine whether fish oil can reduce depression in people with multiple sclerosis (MS) who are mild to moderately depressed and are currently taking antidepressant medication.

Study hypothesis: Three months of fish oil supplementation will improve depression scores on the Montgomery-Asberg depression rating scale (MADRS) or Beck Depression Inventory (BDI) better than placebo.

Conditions

Interventions

DRUG

Fish oil concentrate

fish oil concentrate at a daily dose of 6 grams (2.1 gram EPA and 1.5 gram DHA).

DRUG

Placebo

soybean oil with 1% fish oil at a daily dose of 6 grams

Sponsors & Collaborators

  • National Center for Complementary and Integrative Health (NCCIH)

    collaborator NIH

  • Oregon Health and Science University

    lead OTHER

Principal Investigators

  • Lynne Shinto, ND, MPH · Oregon Health and Science University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-07-31
Primary Completion
2009-06-30
Completion
2009-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00122954 on ClinicalTrials.gov